Antiparasitic drugs such as fenbendazole he caught the attention of researchers studying pancreatic cancer. In early studies, they he shown promise in inhibiting the growth and spread of cancer cells.
Pancreatic cancer is one of the most aggressive forms of cancer, with low survival rates. This disease is known for its late stage diagnosis and limited treatment options. As a result, researchers are constantly looking for new approaches to manage it.
While several early studies he provided initial evidence suggesting that fenbendazole (Panacur, Safe-Guard) has potential in treating various types of cancer, including pancreatic cancer, further research is needed to determine its success and safety in human clinical trials.
Let’s go over existing research and evidence surrounding the use of fenbendazole for pancreatic cancer.
What is fenbendazole?Fenbendazole is a broad-spectrum anthelmintic medication primarily used in veterinary medicine to treat animal gastrointestinal parasites. It belongs to the benzimidazole class of medications and is effective against various parasites, including roundworms, hookworms, whipworms, and certain animal tapeworms.
While fenbendazole was initially formulated for veterinary use, preliminary research suggests that it may prevent cancer cell growth and induce cancer cell death.
Fenbendazole is a veterinary medication and has not been approved by the Food and Drug Administration (FDA) for cancer treatment in humans.
The use of fenbendazole for pancreatic cancer is still experimental, and more studies are needed to determine its success and safety in humans.